Raimon Roura - Grifols SA Non-Member Secretary of the Board
| GRFS Stock | USD 8.44 0.16 1.93% |
Executive
Mr. Raimon Grifols Roura serves as CoChief Executive Officer, Executive Director of Grifols, S.A. since January 1, 2017. He is Associate Partner of the law firm Osborne Clarke in Spain and Board Member of Squadron Reinsurance Ltd, Marca Grifols SL and Arrahona Optimus SL, as well as Patron of Probitas Fundacion Privada. He is a member of the administration bodies of several companies within the Grifols Group. From 2001 to 2015 he held the role of nonmember secretary of the Board of Directors of Grifols, S.A., serving as Director and ViceSecretary of the Board of Directors since 2015. In May 2016 the Board accepted his resignation as vice secretary. He holds a Bachelors degree in Law from Universidad de Barcelona. since 2017.
| Age | 60 |
| Tenure | 8 years |
| Phone | 34 935 712 200 |
| Web | https://www.grifols.com |
Grifols SA Management Efficiency
The company has return on total asset (ROA) of 0.0287 % which means that it generated a profit of $0.0287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0271 %, meaning that it created $0.0271 on every $100 dollars invested by stockholders. Grifols SA's management efficiency ratios could be used to measure how well Grifols SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alan Hippe | Roche Holding Ltd | 56 | |
| Kave Niksefat | Amgen Inc | N/A | |
| Jerry Murry | Amgen Inc | N/A | |
| Vasant Narasimhan | Novartis AG ADR | 48 | |
| David MD | Amgen Inc | 62 | |
| Vasant MD | Novartis AG ADR | 49 | |
| Chirfi Guindo | Merck Company | 58 | |
| Darryl MD | Amgen Inc | N/A | |
| William Winters | Novartis AG ADR | 60 | |
| Joerg Koglin | Merck Company | N/A | |
| Arvind Sood | Amgen Inc | N/A | |
| Giovanni MD | Bristol Myers Squibb | 59 | |
| Bertrand Bodson | Novartis AG ADR | 44 | |
| Catherine Owen | Bristol Myers Squibb | 54 | |
| Dalton III | Merck Company | 58 | |
| Cristina Wilbur | Roche Holding Ltd | 56 | |
| Jacquie CFA | Gilead Sciences | N/A | |
| Monica Tijerina | Gilead Sciences | N/A | |
| John Tsai | Novartis AG ADR | 54 | |
| Peter Dannenbaum | Merck Company | N/A | |
| Tim MBA | Biogen Inc | N/A | |
Management Performance
| Return On Equity | 0.0271 | ||||
| Return On Asset | 0.0287 |
Grifols SA ADR Leadership Team
Elected by the shareholders, the Grifols SA's board of directors comprises two types of representatives: Grifols SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grifols. The board's role is to monitor Grifols SA's management team and ensure that shareholders' interests are well served. Grifols SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grifols SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Camille Alpi, Chief Officer | ||
| Alberto Roura, President Division | ||
| Jose Buenache, CEO Director | ||
| Daniel Coit, Chief Officer | ||
| Thomas Glanzmann, Executive Chairman | ||
| Luis Garon, Managing Grifols | ||
| Alfredo Guerra, CFO and Corporate VP | ||
| Raimon Roura, Non-Member Secretary of the Board | ||
| Miguel Montblanch, President Support | ||
| Alfredo CPA, CFO VP | ||
| Nuria Lapea, Risk Treasury | ||
| Sergio Adell, President Support | ||
| Maria Llano, Chief Officer | ||
| M Tubau, Corporate Affairs | ||
| Vicente Torre, Chief Officer | ||
| Steven JD, Ex Chairman | ||
| Nacho Abia, CEO Director | ||
| Mateo Humbert, Director of Human Resources | ||
| Montserrat Llamas, Chief Officer | ||
| Vctor Deu, Executive Director | ||
| Lluis Gomez, Senior Office | ||
| David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries | ||
| Antonio Martinez, President unit |
Grifols Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Grifols SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0271 | ||||
| Return On Asset | 0.0287 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 16.4 B | ||||
| Shares Outstanding | 257.44 M | ||||
| Shares Owned By Institutions | 58.25 % | ||||
| Number Of Shares Shorted | 3.53 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 0.93 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Grifols Stock Analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.